West Syndrome - Pipeline Insight, 2024

This “West Syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in West Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

West Syndrome: Understanding

West Syndrome: Overview

Infantile spasms are epileptic spasms that occur in infancy or early childhood. These spasms are classically characterized clinically by symmetric, brief jerking spells that involve the head, neck, arms, legs, and abdomen which may consist of flexion, extension, or a combination of flexion-extension. Infantile spasms often are associated with a characteristic pattern on electroencephalogram (EEG) called hypsarrhythmia. When the triad of infantile spasms, hypsarrhythmia, and developmental regression occur together, this triad is termed West Syndrome.

West Syndrome- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the West Syndrome pipeline landscape is provided which includes the disease overview and West Syndrome treatment guidelines. The assessment part of the report embraces, in depth West Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in West Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve in West Syndrome.

This segment of the West Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

West Syndrome Emerging Drugs

AMZ002: AmzellA highly purified sterile injectable product containing a synthetic hormone recognized as the gold standard for the treatment of catastrophic infantile epileptic disease. AMZ002 has completed a Phase I clinical trial. Amzell BV initiate FDA-approved Phase III clinical trial of this innovative injectable treatment for infantile epileptic.

West Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different West Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in West Syndrome

There are approx. 10+ key companies which are developing the therapies for West Syndrome. The companies which have their West Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Amzell

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

West Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

West Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses West Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging West Syndrome drugs.

West Syndrome Report Insights

• West Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

West Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing West Syndrome drugs?
• How many West Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of West Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the West Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for West Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Channel Biosciences
• Ferring Pharmaceuticals
• BioPharm Solutions
• Healx
• Biom Therapeutics

Key Products

• BHV 7000
• AMZ 002
• JBPOS 0101

Research programme: neurological disorder therapeutics- BIO 018


This product will be delivered within 2 business days.